Botanical species · safety record

Lycopodium clavatum

The EFSA Compendium of Botanicals holds 8 constituent measurements for Lycopodium clavatum. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Lycopodium clavatum L.

8Constituent measurements

0Safety records

4Cited sources

317Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 317 licensed products naming Lycopodium clavatum as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Fresh

Source material stated

Aerial parts
Aerial parts extract
Cattle
Dried ripe spores
Dried spores
Herb
Herb extract
Herb top

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Alkaloids	Aerial part of plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Quinolizidine alkaloids	Unspecified	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Quinolizidine alkaloids	Aerial part of plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Huperzine a	Unspecified	Solvent extraction	—	—	No resolvable identifier
Lycopodine	Unspecified	Solvent extraction	—	—	No resolvable identifier
Lycopodine	Unspecified	Solvent extraction	—	—	No resolvable identifier
Nicotine	Unspecified	Solvent extraction	—	—	No resolvable identifier
Quinolizidine alkaloids	Unspecified	Solvent extraction	—	—	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Katakawa, Kazuaki., Mito, Hiroko., Kogure, Noriyuki., Kitajima, Mariko., Wongseripipatana, Sumphan., Arisawa, Munehisa., Takayama, Hiromitsu. Ten new fawcettimine-related alkaloids from three species of Lycopodium. Tetrahedron, 2011, vol. 67, no. 35, p. 6561-6567. DOI
Banerjee, Jhilik., Biswas, Sunipa., Madhu, Nithar Ranjan., Karmakar, Susanta Roy., Biswas, Surjyo Jyoti. A better understanding of pharmacological activities and uses of phytochemicals of Lycopodium clavatum: a review. Journal of pharmacognosy and phytochemistry, 2014, vol. 3, no. 1), 207-21, p. 4 pp.
Pongpamorn, Pornkanok., Wan-erlor, Sakuna., Ruchirawat, Somsak., Thasana, Nopporn. Lycoclavatumide and 8 beta,11 alpha-dihydroxylycopodine, a new fawcettimine and lycopodine-type alkaloid from Lycopodium clavatum . Tetrahedron, 2016, vol. 72, no. 44, p. 7065-7069. DOI
Marion, Leo., Manske, Richard H. F. The alkaloids of Lycopodium species. VI. Lycopodium clavatum L. Canadian journal of research, section b: chemical sciences, 1944, vol. 22B, p. 137-9.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature